+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Laboratory and clinical studies on norfloxacin in the pediatric field



Laboratory and clinical studies on norfloxacin in the pediatric field



Japanese Journal of Antibiotics 43(5): 808-825



In bacteriological, pharmacokinetic and clinical studies on norfloxacin (NFLX, AM-715), the following results were obtained: 1. Antibacterial activity of NFLX, nalidixic acid (NA), amoxicillin (AMPC), cefaclor (CCL), erythromycin (EM) and fosfomycin (FOM) against clinically isolated bacteria was examined, and it was found that MIC80 of NFLX against Staphylococcus aureus was 3.13 .mu.g/ml, thus NFLX exhibited stronger antimicrobial activity than NA, AMPC, CCL, EM and FOM. NFLX also showed good activities to those strains of S. aureus Which were resistance to NA, AMPC, CCL, EM and FOM. 2. MIC80 of NFLX against Escherichia coli was 0.05 .mu.g/ml or lower, thus NFLX showed better activity than NA, AMPC, CCL, EM and FOM. 3. In single oral administration at fasting of NFLX at dose levels of 1.5 .apprx. 2.4 and 2.5 .apprx. 3.4 mg/kg in tablet form mean peak values of serum concentration were 0.32 .mu.g/ml reached in 1 hour and 0.38 .mu.g/ml in 2 hours, T1/2's obtained were 1.7 .apprx. 4.0 and 2.2 .apprx. 2.9 hours and AUC's were 1.54 .+-. 0.52 and 2.02 .+-. 0.93, mg .cntdot. hr/ml, respectively. Urinary recovery rates of 11.6 .apprx. 46.9%, 13.8 .apprx. 35.4% in 6 .apprx. 8 hours were demonstrated with the 2 ranges of dose levels, respectively. 4. NFLX was administrated to 34 patients consisting of 8 cases of acute pneumonia, 3 cases of acute tonsillitis, 3 cases of bacterial colitis, 19 cases of urinary tract infections and 1 case of purulent parotitis. The clinical efficacy rate 97.1% including 34 cases with excellent results in 28, good in 5 and fair in 1. 5. The bacterial eradication rate was 96.8% (30/31) with one exception of a Campylobacter jejuni strain. 6. NFLX was given to patients according to a dosing regimen with 4.5 .apprx. 21.4 mg/kg/day dose levels for 3 doses daily except 1 case of UTI where 2 daily doses were given daily. 7. No adverse reactions were observed. Abnormal laboratory test value was obtained in 1 case where eosinophilia was found. The above results have suggested that NFLX is a useful and safe antimicrobial agent against bacterial infections in children.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 007502534

Download citation: RISBibTeXText

PMID: 2391752


Related references

Laboratory and clinical studies of norfloxacin in pediatric field. Japanese Journal of Antibiotics 43(5): 860-871, 1990

Pharmacokinetics and clinical studies of norfloxacin in the pediatric field. Japanese Journal of Antibiotics 43(5): 901-917, 1990

Basic and clinical studies on norfloxacin in the pediatric field. Japanese Journal of Antibiotics 43(9): 1629-1648, 1990

Pharmacokinetic, bacteriological and clinical studies in the pediatric field on norfloxacin. Japanese Journal of Antibiotics 43(5): 799-807, 1990

Clinical effect of norfloxacin in pediatric field. Japanese Journal of Antibiotics 43(5): 877-883, 1990

Laboratory and clinical studies of PC-904 in pediatric field. Japanese Journal of Antibiotics 31(7): 359-362, 1978

Laboratory and clinical studies cefroxadine in pediatric field. Japanese Journal of Antibiotics 34(12): 1655-1662, 1981

Laboratory and clinical studies of cefmenoxime in the pediatric field. Japanese Journal of Antibiotics 35(11): 2535-2544, 1982

Laboratory and clinical studies of 6059-S in pediatric field. Japanese Journal of Antibiotics 34(5): 800-816, 1981

Laboratory and clinical studies on cefdinir in pediatric field. Japanese Journal of Antibiotics 43(8): 1424-1435, 1990

Laboratory and clinical studies of 9,3"-diacetylmidecamycin in the pediatric field. Japanese Journal of Antibiotics 35(6): 1475-1492, 1982

Laboratory and clinical studies on cefamandole in pediatric field. Japanese Journal of Antibiotics 32(11): 1091-1100, 1979

Laboratory and clinical studies of cefuzonam in pediatric field. Japanese Journal of Antibiotics 40(2): 427-438, 1987

Laboratory and clinical studies of ceftazidime in the pediatric field. Japanese Journal of Antibiotics 37(3): 512-523, 1984

Laboratory and clinical studies on cefminox in the pediatric field. Japanese Journal of Antibiotics 38(3): 766-772, 1985